Hearts & Minds Blog

Resilient and Relentlessly Focused in 2017

Tim Mayleben

President and Chief Executive Officer

Happy New Year! We welcomed 2017 with tremendous momentum as we advanced our bempedoic acid (ETC-1002) pivotal Phase 3 LDL… more

Bempedoic Acid Mechanism of Action Paper Published in Nature Communications: Q&A with the Authors

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

Narendra Lalwani, PhD, MBA, FAHA

Executive Vice President, Research and Development, and Chief Operating Officer

Steve Pinkosky

Senior Scientist, Head of Translational Research

As you may have seen, Esperion scientists and collaborators recently published the definitive paper on the mechanism of action for… more

AHA 2014 Scientific Sessions: IMPROVE-IT Results Reported and What They Mean for the Future of ETC-1002

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

Tim Mayleben

President and Chief Executive Officer

Last month, the American Heart Association (AHA) held its annual Scientific Sessions in Chicago, IL where presenters and attendees gathered… more

Equity Financing Now Complete: Moving ETC-1002 into Phase 3

Tim Mayleben

President and Chief Executive Officer

October was a very big month for our company! ¬†Esperion not only announced positive top-line results from the ETC-1002-008 Phase… more

Esperion Investor Day: Lighting the Way for Phase 2b Results

Tim Mayleben

President and Chief Executive Officer

On July 29th, Esperion held its inaugural investor day in New York City, with a tightly-packed agenda for the half-day… more